Goldline Pharmaceutical IPO Details
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Face Value | ā¹10 Per Equity Share |
| IPO Price Band | ā¹41 to ā¹43 Per Share |
| Issue Size | Approx ā¹12 Crores |
| Fresh Issue | Approx ā¹12 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Goldline Pharmaceutical IPO Review & Key Points
- Review: May Apply
Goldline Pharmaceutical IPO Market Lot
The Goldline Pharmaceutical IPO minimum market lot is 6,000 shares with ā¹2,58,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 6,000 | ā¹2,58,000 |
| Retail Maximum | 2 | 6,000 | ā¹2,58,000 |
| S-HNI Minimum | 3 | 9,000 | ā¹3,87,000 |
| S-HNI Maximum | 7 | 21,000 | ā¹9,03,000 |
| B-HNI Minimum | 8 | 24,000 | ā¹10,32,000 |
IPO Reservation
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | 7,32,000 Shares | 27.11% |
| QIB (Ex. Anchor) | 5,40,000 Shares | 20.00% |
| NII Shares Offered | 3,90,000 Shares | 14.44% |
| Retail Shares Offered | 9,00,000 Shares | 33.33% |
Goldline Pharmaceutical IPO Anchor Investors
| Anchor Bidding Date | May 11, 2026 |
| Anchor Investors List | |
| Shares Offered | 7,32,000 Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | 2026 |
| lock-in period end date 50% shares (90 Days) | 2026 |
Goldline Pharmaceutical IPO Dates
The Goldline Pharmaceutical IPO date is May 12 and the close date is May 14. The Goldline Pharmaceutical IPO allotment will be finalized on May 15 and the IPO listing on May 19.
| IPO Open Date: | May 12, 2026 |
| IPO Close Date: | May 14, 2026 |
| Basis of Allotment: | May 15, 2026 |
| Refunds: | May 18, 2026 |
| Credit to Demat Account: | May 18, 2026 |
| IPO Listing Date: | May 19, 2026 |
| IPO Bidding Cut-off Time: | May 14, 2026 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
| Promoter Holding Post Issue | 96,00,000 | -% |
Objects of the Issue & Utilisation of Proceeds
| Purpose | Crores |
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | ā¹8.90 |
| General Corporate Purpose | ā¹- |
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy.
The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
Goldline Pharmaceutical IPO Company Financial Report
Amount ā¹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ā¹19.85 | ā¹19.45 | ā¹0.26 | ā¹19.39 |
| 2024 | ā¹23.57 | ā¹21.04 | ā¹1.81 | ā¹22.93 |
| 2025 | ā¹28.06 | ā¹24.20 | ā¹2.83 | ā¹26.28 |
| Dec 2025 | ā¹21.41 | ā¹18.40 | ā¹2.22 | ā¹27.40 |
Goldline Pharmaceutical IPO Valuation – FY2025
Check Goldline Pharmaceutical IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 35.84% |
| ROCE: | 38.46% |
| EBITDA Margin: | 20.79% |
| PAT Margin: | 10.10% |
| Debt to equity ratio: | 1.50 |
| Earning Per Share (EPS): | ā¹4.10 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 27.37% |
| Net Asset Value (NAV): | ā¹12.38 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Mono Pharmacare Limited | 1.75 | 7.57 | 9.90% | 17.66 | 168.34 Cr. |
| Chandra Bhagat Pharma Limited | 1.14 | 28.94 | 2.86% | 39.72 | 86.72 Cr. |
IPO Lead Managers aka Merchant Bankers
- Cumulative Capital Pvt. Ltd.
Company Address
Goldline Pharmaceutical Ltd.
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Phone: +91 712 2786666
Email: info@goldlinepharma.in
Website: http://www.goldlinepharma.in/
IPO Registrar
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Goldline Pharmaceutical IPO FAQs
What is Goldline Pharmaceutical IPO?
When Goldline Pharmaceutical IPO will open for subscription?
What is Goldline Pharmaceutical IPO Investors Portion?
How to Apply the Goldline Pharmaceutical IPO?
What is Goldline Pharmaceutical IPO Issue Size?
What is Goldline Pharmaceutical IPO Price Band?
What is Goldline Pharmaceutical IPO Lot Size?
What is the Goldline Pharmaceutical IPO Allotment Date?
What is the Goldline Pharmaceutical IPO Listing Date?
Note: The Goldline Pharmaceutical IPO price band and date are officially announced. The (Goldline Pharmaceutical IPO grey market premium) will be added to the IPO GMP page as it will start).
